<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611477</url>
  </required_header>
  <id_info>
    <org_study_id>NI/190701/SYNBIOTIC365/OO</org_study_id>
    <nct_id>NCT04611477</nct_id>
  </id_info>
  <brief_title>Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals</brief_title>
  <acronym>Obesity</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy of Synbiotic 365 on Body Composition in Overweight and Obese Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of Synbiotic 365 (Version 5 and 7) on body composition in overweight and&#xD;
      obese individuals as measured by change in body mass index (BMI) and the percentage of body&#xD;
      fat from Day 0 to Day 84 when compared to placebo by Dual Energy X-ray Absorptiometry scan&#xD;
      (DEXA) for body composition (Body Mass Index, Lean Body Mass, Body Fat, Fat Free Mass).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Actual">October 29, 2021</completion_date>
  <primary_completion_date type="Actual">October 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body mass index (BMI) and the percentage of body fat f</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
    <description>To investigate the effect of Synbiotic 365 (Version 5 and 7) on body composition in overweight and obese individuals as measured by change in body mass index (BMI) and the percentage of body fat from Day 0 to Day 84 when compared to placebo by Dual Energy X-ray Absorptiometry scan (DEXA) for body composition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Total body weight change in comparison to placebo on day 28, 56 and 84, from baseline, as assessed by weighing scale method.</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in central obesity in comparison to placebo on day 28, 56 and 84, from baseline as assessed by the anthropometric index of waist-to-hip ratio.</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in coronary risk in comparison to placebo on day 84 from baseline.</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in blood glucose metabolism in comparison to placebo on day 84 from baseline as assessed by HOMA-IR [(fasting Glucose x fasting Insulin) /405)].</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in systemic inflammation in comparison to placebo on day 84 from baseline as assessed by hs-CRP test.</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in health-related quality of life (HRQL) scores in comparison to placebo on day 28, 56 and 84 from baseline, as assessed by Gastrointestinal Quality of Life Index (GIQLI).</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in satiety in comparison to placebo on day 28, 56 and 84, from baseline as assessed by the Three-Factor Eating Questionnaire (TFEQ) for satiety.</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• The change in vital signs monitoring on all the study visits from baseline.</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• The change in liver and renal safety parameters.</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Adverse and serious adverse events recorded during the study duration on IP consumption, as compared to placebo.</measure>
    <time_frame>Day 0 (Baseline) to Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule/day to be taken orally 30 minutes before breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synbiotic365 Ver 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule/day to be taken orally 30 minutes before breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synbiotic365 Ver 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule/day to be taken orally 30 minutes before breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rice Hulk</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Synbiotic365 Ver 5</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Synbiotic365 Ver 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Synbiotic365 Ver 7</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Synbiotic365 Ver 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants meeting ALL of the following criteria will be recruited for the trial:&#xD;
&#xD;
          -  Male and female participants aged ≥30 and ≤60 years.&#xD;
&#xD;
          -  Participants with a BMI in the range of ≥25 to 34.9 kg/m2.&#xD;
&#xD;
          -  Normal levels of SGOT and SGPT i.e. up to 2.5 times of upper limit of reference range.&#xD;
&#xD;
          -  Normal level of Creatinine i.e. up to 1.5 times of upper limit of reference range.&#xD;
&#xD;
          -  Alkaline Phosphatase i.e. up to 1.5 times of upper limit of reference range&#xD;
&#xD;
          -  Participants having At least 3 of the following five metabolic risk factors:&#xD;
&#xD;
             i. Waist circumference: Men: ≥ 102 cm (40.15 inches); Women ≥88 cm (34.65 inches) ii.&#xD;
             Triglycerides levels &gt;150 mg/dL iii. Blood pressure ≥130 mm Hg (systolic, SBP) and/or&#xD;
             ≥85 mm Hg (diastolic, DBP); iv. Fasting blood glucose ≥ 100 mg/ dL v. Low HDL level:&#xD;
             Men: &lt; 40 mg/dL; Women: &lt; 50 mg/dL.&#xD;
&#xD;
          -  Participants willing to complete all the study procedures including study-related&#xD;
             questionnaires and comply with the study requirements.&#xD;
&#xD;
          -  Participants willing to abstain from the restricted supplements and medications prior&#xD;
             to inclusion and throughout the study period.&#xD;
&#xD;
          -  Participants ready to give voluntary, written, informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
          -  Participants willing to continue the same diet and exercise regime throughout the&#xD;
             study period.&#xD;
&#xD;
          -  Individuals having a history of smoking or currently smoking and also using any form&#xD;
             of tobacco preparations.&#xD;
&#xD;
          -  Participants diagnosed with type II diabetes mellitus or undiagnosed cases of&#xD;
             hyperglycemia with fasting blood sugar &gt; 170 mg/dl.&#xD;
&#xD;
          -  Participants with blood pressure ≥150 mm Hg (systolic, SBP) and/or ≥ 99 mm Hg&#xD;
             (diastolic, DBP)&#xD;
&#xD;
          -  Inability to walk independently&#xD;
&#xD;
          -  History of significant weight instability (defined as &gt; 2 kg of weight loss over last&#xD;
             3 months)&#xD;
&#xD;
          -  Participants currently on diuretics, metformin or thyroid supplements.&#xD;
&#xD;
          -  Presence of unstable, acutely symptomatic, or life-limiting illness.&#xD;
&#xD;
          -  Any significant neurological and psychiatric condition which may affect the&#xD;
             participation and inference of the study's end points.&#xD;
&#xD;
          -  Unwillingness or inability to be randomized to any one of the three intervention&#xD;
             groups&#xD;
&#xD;
          -  Continuous participation in randomly assigned lifestyle intervention program for six&#xD;
             months.&#xD;
&#xD;
          -  Bilateral hip replacements.&#xD;
&#xD;
          -  Unable to give consent.&#xD;
&#xD;
          -  Known cases of hypothyroidism.&#xD;
&#xD;
          -  Abnormal TSH value, out of reference range (&lt;0.4µIU/mL and &gt; 4.0µIU/mL).&#xD;
&#xD;
          -  Females with the history of irregular menses or any other gynecological disorder such&#xD;
             as (polycystic ovarian syndrome (PCOS), hormonal disturbances, etc).&#xD;
&#xD;
          -  History or presence of clinically significant renal, hepatic, endocrine, biliary,&#xD;
             gastrointestinal, pancreatic disorders, that in the judgment of the investigator,&#xD;
             would interfere with the participant's ability to provide informed consent, comply&#xD;
             with the study protocol (which might confound the interpretation of the study&#xD;
             results), or put the participant at undue risk.&#xD;
&#xD;
          -  Use of any psychotropic medication such as monoamine oxidase (MAO) inhibitors,&#xD;
             anxiolytics, mood stabilizers, stimulants, etc. throughout the study.&#xD;
&#xD;
          -  Exposure to any non-registered drug product within 3 months prior to the screening&#xD;
             visit.&#xD;
&#xD;
          -  Participants currently using or having a history of herbal/nutraceutical supplements&#xD;
             usage for weight loss in last 3 months.&#xD;
&#xD;
          -  Participants currently on vitamin supplements will be rescreened after a washout&#xD;
             period of 2 weeks.&#xD;
&#xD;
          -  Females who are pregnant/planning to be pregnant/lactating or taking any oral&#xD;
             contraceptives.&#xD;
&#xD;
          -  Participants with heavy alcohol consumption, defined as&#xD;
&#xD;
               -  For men: More than 14 standard alcoholic drink (SAD)/week or more than 4 SAD in a&#xD;
                  day.&#xD;
&#xD;
               -  For women: More than 7 SAD/week or more than 3 SAD in a day.&#xD;
&#xD;
          -  Binge drinkers, defined as 4 or more SAD for women, and 5 or more SAD for men, in a&#xD;
             2-hour time frame.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parag Dr. Salvi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shri Madhumadhav Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shri Madhumadhav Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

